Healthcare / Medical DevicesLSE
$0.47
-0.00 (-0.84%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 22%
FCF escenarios
weak_data · normalized FCF $-409000.00 · quality 62.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
26/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$4M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-22.7%
↓Gross Margin
28.8%
↓Debt/Equity
0.15
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2021–2024 · 3 años de histórico normalizado
Revenue CAGR
+9.4%
FCF CAGR
—
FCF margin
-3.4%
FCF / Net income
0.21x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $11.9M · net income $-1.9M · FCF $-409000.0
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $11.9M | $11.9M | $12.0M | $11.3M | $9.1M |
| Net Income | $-1.9M | $-1.9M | $-509000.00 | $264000.00 | $-456000.00 |
| EBITDA | $-99000.00 | $-99000.00 | $161000.00 | $628000.00 | $247000.00 |
| EPS | — | — | -0.00 | 0.00 | -0.00 |
| Gross Margin | 28.8% | 28.8% | 28.7% | 34.6% | 34.3% |
| Operating Margin | -5.3% | -5.3% | -4.9% | 0.6% | -2.8% |
| Net Margin | -16.3% | -16.3% | -4.2% | 2.3% | -5.0% |
| Balance Sheet | |||||
| Debt/Equity | 0.15 | 0.15 | 0.16 | 0.20 | 0.26 |
| Current Ratio | 1.48 | 1.48 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-409000.00 | $-409000.00 | $-288000.00 | $-592000.00 | $-1.1M |
| Returns | |||||
| ROE | -22.7% | -22.7% | -4.9% | 2.4% | -4.3% |
| Valuation | |||||
| P/E | — | — | — | 5333.33 | — |
| EV/EBITDA | — | — | 3482.30 | 2384.52 | 8358.17 |
| P/B | 51.44 | 51.44 | 53.43 | 136.60 | 193.67 |
| Growth & Yield | |||||
| Revenue Growth | -0.6% | -0.6% | 5.9% | 24.3% | — |
| EPS Growth | — | — | -300.0% | 160.0% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-32.7%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.00 → n/d
Residual
-32.7%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.